A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic
Introduction: Blood-based biomarkers for Alzheimer's disease (AD) have been widely studied, but direct comparisons of several biomarkers in clinical settings remain limited. Methods: In this cross-sectional study, plasma biomarkers from 197 participants in the BIODEGMAR cohort (Hospital del Mar...
| Autores: | , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2025 |
| País: | España |
| Institución: | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| Repositorio: | Recercat. Dipósit de la Recerca de Catalunya |
| OAI Identifier: | oai:recercat.cat:10230/70380 |
| Acceso en línea: | http://hdl.handle.net/10230/70380 http://dx.doi.org/10.1002/alz.14609 |
| Access Level: | acceso abierto |
| Palabra clave: | Alzheimer's disease Amyloid‐β Biomarker Diagnosis Phosphorylated tau Plasma |
| id |
ES_d986ca1ffee829b2ffd5b54e0efa54be |
|---|---|
| oai_identifier_str |
oai:recercat.cat:10230/70380 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| dc.title.none.fl_str_mv |
A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic |
| title |
A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic |
| spellingShingle |
A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic Anastasi, Federica Alzheimer's disease Amyloid‐β Biomarker Diagnosis Phosphorylated tau Plasma |
| title_short |
A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic |
| title_full |
A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic |
| title_fullStr |
A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic |
| title_full_unstemmed |
A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic |
| title_sort |
A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic |
| dc.creator.none.fl_str_mv |
Anastasi, Federica Fernández-Lebrero, Aida Ortiz Romero, Paula, 1994- Torres-Torronteras, Javier González Escalante, Armand Contador, Jose García Escobar, Greta Manero, Rosa María Navalpotro-Gómez, Irene Jiménez-Moyano, Esther Grau-Rivera, Oriol Campo, Marta del Puig-Pijoan, Albert Suárez-Calvet, Marc |
| author |
Anastasi, Federica |
| author_facet |
Anastasi, Federica Fernández-Lebrero, Aida Ortiz Romero, Paula, 1994- Torres-Torronteras, Javier González Escalante, Armand Contador, Jose García Escobar, Greta Manero, Rosa María Navalpotro-Gómez, Irene Jiménez-Moyano, Esther Grau-Rivera, Oriol Campo, Marta del Puig-Pijoan, Albert Suárez-Calvet, Marc |
| author_role |
author |
| author2 |
Fernández-Lebrero, Aida Ortiz Romero, Paula, 1994- Torres-Torronteras, Javier González Escalante, Armand Contador, Jose García Escobar, Greta Manero, Rosa María Navalpotro-Gómez, Irene Jiménez-Moyano, Esther Grau-Rivera, Oriol Campo, Marta del Puig-Pijoan, Albert Suárez-Calvet, Marc |
| author2_role |
author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Alzheimer's disease Amyloid‐β Biomarker Diagnosis Phosphorylated tau Plasma |
| topic |
Alzheimer's disease Amyloid‐β Biomarker Diagnosis Phosphorylated tau Plasma |
| description |
Introduction: Blood-based biomarkers for Alzheimer's disease (AD) have been widely studied, but direct comparisons of several biomarkers in clinical settings remain limited. Methods: In this cross-sectional study, plasma biomarkers from 197 participants in the BIODEGMAR cohort (Hospital del Mar, Barcelona) were analyzed. Participants were classified based on AD cerebrospinal fluid (CSF) core biomarkers. We assessed the ability of plasma p-tau181, p-tau217, p-tau231, t-tau, and Aβ42/40 to classify Aβ pathology status. Results: Plasma p-tau biomarkers had a greater diagnostic performance and larger effect sizes compared to t-tau and Aβ42/40 assays in detecting Aβ pathology. Among them, plasma p-tau217 consistently outperformed the others, demonstrating superior area under the curves. Furthermore, p-tau217 showed the strongest correlation between plasma and CSF levels, underscoring its potential as a reliable surrogate for CSF biomarkers. Discussion: Several plasma biomarkers, targeting different epitopes and using different platforms, demonstrated high performance in detecting AD in a memory clinic setting. Highlights: Plasma p-tau biomarkers demonstrated higher diagnostic performance and larger effect sizes than t-tau and Aβ42/40 assays in detecting Alzheimer's disease. Among the p-tau biomarkers, p-tau217 assays consistently outperformed the others, providing superior classification of Aβ pathology status across different phosphorylation sites. p-tau217 assays showed the strongest correlation between plasma and CSF levels, indicating its potential as a reliable surrogate for CSF biomarkers. Several plasma p-tau biomarkers can be used in a specialized memory clinic to accurately detect Alzheimer's disease. |
| publishDate |
2025 |
| dc.date.none.fl_str_mv |
2025 2025 2025 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/10230/70380 http://dx.doi.org/10.1002/alz.14609 http://hdl.handle.net/10230/70380 |
| url |
http://hdl.handle.net/10230/70380 http://dx.doi.org/10.1002/alz.14609 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.relation.none.fl_str_mv |
Alzheimers Dement. 2025 Feb;21(2):e14609 info:eu-repo/grantAgreement/EC/HE/101053962 info:eu-repo/grantAgreement/EC/H2020/948677 info:eu-repo/grantAgreement/EC/H2020/847648 |
| dc.rights.none.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf application/pdf |
| dc.publisher.none.fl_str_mv |
Wiley |
| publisher.none.fl_str_mv |
Wiley |
| dc.source.none.fl_str_mv |
reponame:Recercat. Dipósit de la Recerca de Catalunya instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| instname_str |
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| reponame_str |
Recercat. Dipósit de la Recerca de Catalunya |
| collection |
Recercat. Dipósit de la Recerca de Catalunya |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869421395109216256 |
| spelling |
A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinicAnastasi, FedericaFernández-Lebrero, AidaOrtiz Romero, Paula, 1994-Torres-Torronteras, JavierGonzález Escalante, ArmandContador, JoseGarcía Escobar, GretaManero, Rosa MaríaNavalpotro-Gómez, IreneJiménez-Moyano, EstherGrau-Rivera, OriolCampo, Marta delPuig-Pijoan, AlbertSuárez-Calvet, MarcAlzheimer's diseaseAmyloid‐βBiomarkerDiagnosisPhosphorylated tauPlasmaIntroduction: Blood-based biomarkers for Alzheimer's disease (AD) have been widely studied, but direct comparisons of several biomarkers in clinical settings remain limited. Methods: In this cross-sectional study, plasma biomarkers from 197 participants in the BIODEGMAR cohort (Hospital del Mar, Barcelona) were analyzed. Participants were classified based on AD cerebrospinal fluid (CSF) core biomarkers. We assessed the ability of plasma p-tau181, p-tau217, p-tau231, t-tau, and Aβ42/40 to classify Aβ pathology status. Results: Plasma p-tau biomarkers had a greater diagnostic performance and larger effect sizes compared to t-tau and Aβ42/40 assays in detecting Aβ pathology. Among them, plasma p-tau217 consistently outperformed the others, demonstrating superior area under the curves. Furthermore, p-tau217 showed the strongest correlation between plasma and CSF levels, underscoring its potential as a reliable surrogate for CSF biomarkers. Discussion: Several plasma biomarkers, targeting different epitopes and using different platforms, demonstrated high performance in detecting AD in a memory clinic setting. Highlights: Plasma p-tau biomarkers demonstrated higher diagnostic performance and larger effect sizes than t-tau and Aβ42/40 assays in detecting Alzheimer's disease. Among the p-tau biomarkers, p-tau217 assays consistently outperformed the others, providing superior classification of Aβ pathology status across different phosphorylation sites. p-tau217 assays showed the strongest correlation between plasma and CSF levels, indicating its potential as a reliable surrogate for CSF biomarkers. Several plasma p-tau biomarkers can be used in a specialized memory clinic to accurately detect Alzheimer's disease.Federica Anastasi receives funding from the JDC2022-049347-I grant, funded by the MCIU/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR. Henrik Zetterberg is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union's Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer's Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). Marc Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through the project SLD077/21/000001; Project “PI19/00155″ and “PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from ”la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).Wiley202520252025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/70380http://dx.doi.org/10.1002/alz.14609http://hdl.handle.net/10230/70380reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésAlzheimers Dement. 2025 Feb;21(2):e14609info:eu-repo/grantAgreement/EC/HE/101053962info:eu-repo/grantAgreement/EC/H2020/948677info:eu-repo/grantAgreement/EC/H2020/847648© 2025 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/703802026-05-29T05:05:01Z |
| score |
15,811543 |